Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to -$23.2 million.

  • Coherus Oncology's Other Working Capital Changes fell 156020.15% to -$23.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.5 million, marking a year-over-year decrease of 1354.78%. This contributed to the annual value of -$5.5 million for FY2024, which is 6613.43% up from last year.
  • Latest data reveals that Coherus Oncology reported Other Working Capital Changes of -$23.2 million as of Q3 2025, which was down 156020.15% from $5.2 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Other Working Capital Changes peaked at $19.0 million during Q3 2022, and registered a low of -$23.2 million during Q3 2025.
  • Moreover, its 5-year median value for Other Working Capital Changes was $761000.0 (2021), whereas its average is -$815368.4.
  • As far as peak fluctuations go, Coherus Oncology's Other Working Capital Changes surged by 173742.75% in 2022, and later crashed by 156020.15% in 2025.
  • Quarter analysis of 5 years shows Coherus Oncology's Other Working Capital Changes stood at $761000.0 in 2021, then rose by 20.24% to $915000.0 in 2022, then crashed by 695.96% to -$5.5 million in 2023, then skyrocketed by 102.04% to $111000.0 in 2024, then crashed by 20990.09% to -$23.2 million in 2025.
  • Its Other Working Capital Changes stands at -$23.2 million for Q3 2025, versus $5.2 million for Q2 2025 and $5.3 million for Q1 2025.